$ cat ./records/gates-foundation-funding-led-to-who-approval-of-the-worlds-first--2021.txt
Gates Foundation funding led to WHO approval of the world's first malaria vaccine
[RECORD.TXT] · cat --full
After more than a decade of Gates Foundation-funded clinical trials, the World Health Organization recommended Mosquirix (RTS,S) — the world's first vaccine against any parasitic disease — for broad use in children in sub-Saharan Africa. Phase 3 trials involving over 15,000 children showed the vaccine reduced malaria cases by approximately 30% and severe malaria cases in young children by 26%. The Foundation's investment was critical to keeping the trials funded through phases that produced insufficient commercial return to attract private investors.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Backed the first field release of gene-drive mosquitoes to fight malaria in Africa
Next →
Scientists Slam the Gates-Funded IHME's Influential but Inaccurate COVID Models
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.